This article describes the planned analyses for the LAST ACT clinical trial, in which corticosteroids (or placebo) were given to HIV-negative adults with tuberculous meningitis stratified by their leukotriene A4 hydrolase (LTA4H) genotype. The gene discussed is LTA4H; the disease is meningeal tuberculosis.